Maximilian Meyer

university psychiatric clinics basel

H指数:10

被引数:324

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Recreational cannabis access via pharmacies: A 1-year Swiss study on cannabis use and mental health

通过药房获取娱乐大麻：一项为期1年的瑞士研究，关于大麻使用与心理健康

Drug and Alcohol Dependence

IF3.6

2026-09-050

OAAI

Operational and clinical procedures of heroin-assisted treatment in Switzerland: a nation-wide survey study

瑞士海洛因辅助治疗项目的操作与临床程序：一项全国性调查研究的报告

Harm Reduction Journal

IF4

2025-10-230

OAAI

Corrigendum/Erratum to “Opioid agonist treatment in transition: A cross-country comparison between Austria, Germany and Switzerland” [Drug Alcohol Depend. 254 (2024) 111036]

勘误/更正：“阿片受体激动剂治疗过渡：奥地利、德国和瑞士的跨国比较”[Drug Alcohol Depend. 254 (2024) 111036]

Drug and Alcohol Dependence

IF3.6

2025-09-260

OAAI

Pharmacokinetics and Pharmacodynamics of Intranasal Diacetylmorphine in Heroin-Assisted Treatment for Severe Opioid Use Disorder

经鼻二乙酰吗啡在严重阿片类药物使用障碍的阿片类药物辅助治疗中的药代动力学和药效学

CNS Drugs

IF7.4

2025-06-070

OAAI

Effects of legal access versus illegal market cannabis on use and mental health: A randomized controlled trial

合法途径与非法市场大麻使用对使用行为和心理健康的影响：一项随机对照试验

ADDICTION

IF5.3

2025-04-280

OAAI

Stability of exercise addiction symptoms and co-occurring mental disorders - a follow-up study

运动成瘾症状与共患精神障碍的稳定性——一项随访研究

FRONTIERS IN PSYCHIATRY

IF3.2

2025-03-270

Diversion of Diacetylmorphine in Heroin-Assisted Treatment: A Focus Group Study among Patients and Treatment Providers

海洛因辅助治疗中二乙酰吗啡的分流：患者和治疗提供者的焦点小组研究

EUROPEAN ADDICTION RESEARCH

IF2.3

2025-03-130

Relative risks of adverse effects across different opioid agonist treatments-A systematic review and meta-analysis

不同阿片类激动剂治疗的不良反应的相对风险-系统评价和荟萃分析

ADDICTION

IF5.3

2025-02-090

Cannabinoids for treating psychiatric disorders in youth: a systematic review of randomized controlled trials

CHILD AND ADOLESCENT PSYCHIATRY AND MENTAL HEALTH

IF4.6

2024-12-180

OAAI

Brain alterations in individuals with exercise dependence: A multimodal neuroimaging investigation

JOURNAL OF BEHAVIORAL ADDICTIONS

IF6.2

2024-06-260

OAAI

Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder

clinical psychology science and practice

IF3.2

2024-06-182

OAAI

Cannabis use and its association with psychopathological symptoms in a Swiss adult population: a cross-sectional analysis

FRONTIERS IN PUBLIC HEALTH

IF3.4

2024-05-222

OAAI

Prolonged diacetylmorphine take-home during the COVID-19 pandemic-Results of a retrospective cohort study

新型冠状病毒肺炎大流行期间延长二乙酰吗啡带回家-回顾性队列研究的结果

ADDICTION

IF5.3

2024-04-210

PRE

Opioid agonist treatment in transition: A cross-country comparison between Austria, Germany and Switzerland

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2024-01-014

OAAI

Shifting drug markets in North America - a global crisis in the making?

international journal of mental health nursing

IF3.8

2023-10-2511

OAAI

Sexual dysfunction prevalence, risk factors, and help-seeking behavior in opioid agonist treatment and general psychiatry: a cross-sectional study

FRONTIERS IN PSYCHIATRY

IF3.2

2023-08-070

OAAI

Quality of life of patients treated with opium tincture or methadone: A randomized controlled trial

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2023-08-011

PRE

Benzodiazepine use, quality of life and psychiatric symptom burden in oral and injectable opioid agonist treatment: a cross-sectional study

clinical psychology science and practice

IF3.2

2023-07-182

OAAI

A Call for an Evidence-Based Strategy Against the Overdose Crisis

CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE

IF3.8

2023-07-125

OAAI

Effects of cannabis regulation in Switzerland: Study protocol of a randomized controlled trial

FRONTIERS IN PSYCHIATRY

IF3.2

2023-03-233

OAAI

Maximilian Meyer

个人简介

教育背景

工作经历

荣誉奖项

研究方向